139 226

Cited 0 times in

신이식환자에서 산디문 뉴오랄로 전환후 효과 및 안정성에 관한 20주간의 추적보고

Other Titles
 Conversion from SandimmunR to Sandimmun NeoralR in Patients with Stable Renal Allografts : 20 Weeks Follow - up Study 
Authors
 김유선  ;  김명수  ;  변창규  ;  김승기  ;  김순일  ;  김수현  ;  박기일 
Citation
 Journal of the Korean Society for Transplantation, Vol.9(1) : 77-82, 1995-12 
Journal Title
Journal of the Korean Society for Transplantation(대한이식학회지)
ISSN
 1298-1711 
Issue Date
1995-12
Abstract
Recently a new formulation of CsA(Sandimmun Neoral), based on microemulsion technology, has been developed and became available. This improved galenic technology allows more predictable and consistent absorption, thus minimizing inter-patient and intra-patient variability and permitting a more predictable whole blood CsA concentration.
The objectives of this study are 1) to assess that safety and tolerability are comparable in stable renal transplant patients when switched from Sandimmun to
Sandimmun Neoral and 2) to assess the ability of Sandimmun Neoral to maintain CsA blood trough levels in the predefined therapeutic window. A total of 48 stable renal transplant patients from our hospital were entered. These patients had to have stable graft function under CsA based immunosuppression and at least 6 months have passed since their first graft. After a two week run-in phase, patients were randomized in a 4 : 1 ratio to switch to Sandimmun Neoral on a 1 : 1 dose level basis or continue Sandimmun for a 20 week period respectively. The results of our research are as following:
1) There was no differences between the groups in terms of sex, age and time interval between transplantation and entry of the study.
2) Mean CsA blood level in Sandimmun control group was fluctuated with about 22.9% width of increment or decrement during study period. However, in Sandimmun Neoral group, mean blood level was steady increased to 17.5% comparing that of time of study entry, which made the required dose 13.3% lower at 20th week.
3) Serum creatinine did not change significantly through the entire study period in both groups.
4) Episodes of infection and occurrence of liver dysfunction in both groups were comparable. There was no episodes of acute rejection requiring treatment in both
groups.
The tolerability and safety of Sandimmun Neoral is equivalent to that of Sandimmun. And lower doses of Sandimmun Neoral than of conventional Sandimmun were required because of a better absorption of Sandimmun Neoral to achieve a predefined therapeutic CsA concentration.
Files in This Item:
T199502161.pdf Download
DOI
10.4285/.1995.9.1.77
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Soon Il(김순일) ORCID logo https://orcid.org/0000-0002-0783-7538
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/186660
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links